Vegunta Rathnamitreyee, Harel Ronen, Steinberg Amir
Internal Medicine, Westchester Medical Center, Valhalla, USA.
Hematology and Oncology, Crystal Run Healthcare, Middletown, USA.
Cureus. 2022 Jun 23;14(6):e26240. doi: 10.7759/cureus.26240. eCollection 2022 Jun.
Chemotherapy has been the standard of treatment for acute myeloid leukemia (AML). With the emergence of new therapies for AML like gemtuzumab-ozogamicin and FLT3 inhibitors, such as sorafenib, midostaurin, and gilteritinib, the optimal dose of chemotherapy and safety profile in different age groups when combined with these new therapies is yet to be established. There are limited data on the treatment of AML by combining intensified daunorubicin (doses of 90 mg/m) with gemtuzumab-ozogamicin (GO). We report a young adult with favorable-risk AML treated with daunorubicin at a dose of 90 mg/m combined with GO, who had a complete response after induction but had a profound nadir of platelet count after induction and consolidation.
化疗一直是急性髓系白血病（AML）的标准治疗方法。随着针对AML的新疗法如吉妥珠单抗-奥唑米星以及FLT3抑制剂（如索拉非尼、米哚妥林和吉列替尼）的出现，化疗的最佳剂量以及在不同年龄组中与这些新疗法联合使用时的安全性尚未确定。关于将强化柔红霉素（剂量为90mg/m）与吉妥珠单抗-奥唑米星（GO）联合用于治疗AML的数据有限。我们报告了一名低危AML青年成人患者，接受了剂量为90mg/m的柔红霉素联合GO治疗，诱导治疗后获得完全缓解，但诱导和巩固治疗后血小板计数出现显著最低点。
